NeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in Adults

Stock Information for Kaival Brands Innovations Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Kaival Brands Innovations Group Inc.

Beyond Air® Announces Transition of Chief Financial Officer
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
Beyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.